CHA2DS2-VASc Score is a Predictor of No-Reflow in Patients with ST-Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Intervention

Abstract

Abstract Background regardless of the magnitude of the infarction, no-reflow is a source of numerous problems, including heart failure, stroke, and death. The CHA2DS2-VASc score is a combination of many risk variables for thromboembolic lesions, the most serious consequences of atrial fibrillation. Current guidelines propose using the CHA2DS2-VASc risk score to estimate thromboembolic events in individuals with atrial fibrillation. It has been demonstrated to be a predictor of problems following acute coronary crises. Aim of the Work to assess the role of CHA2DS2-VASc score in prediction of the no-reflow among patients with ST-segment elevation myocardial infarction (STEMI) who was treated with primary PCI. Subjects and Methods this is a prospective observational study which was done at cardiology department of Ain Shams University on 300 patients. Results the most frequent factor was female sex (43.7%), followed by Diabetes mellitus (27.0%) according to CHA2DS2-VASc score. CHA2DS2-VASc score items statistically were significantly more frequent in no reflow cases except Age ≥75. CHA2DS2-VASc score and its modification significantly had low diagnostic performance in predicting no reflow. Modified was higher than original. Conclusion all CHA2DS2-VASC items were proved to be factors affecting no reflow occurrence in the Egyptian population except Age ≥75 and congestive heart failure due to their low prevalence. The CHA2DS2-VASC score had no high diagnostic characteristics in Egyptian population, the postulated modification of CHA2DS2-VASC score gave no better diagnostic characteristics.